CollPlant Biotechnologies Ltd - ADR

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

rhCollagen-based regenerative breast implants address $2.8 billion global breast implant market with revolutionary and potentially safer new product Regenerative breast implants for aesthetic and reconstructive procedures including postmastectomy for cancer patients The study is planned to be concluded within six months REHOVOT, Israel , June 28, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market. "This study is a quantum leap in the development of 3D bioprinted regenerative breast implants," said Yehiel Tal, CollPlant's Chief Executive Officer.

CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

Co-development of rhCollagen-based dermal and soft tissue filler products with AbbVie is advancing according to plan Launch of large animal study for Company's 3D bioprinted regenerative breast implant program is on track for Q2 2022 Initiate development of a 3D bioprinted tissue model of the human intestine to support drug discovery and personalized medicine for inflammatory bowel diseases in Q3 2022 Reports strong balance sheet with cash and cash equivalents of $41M as of March 31, 2022 REHOVOT, Israel , May 26, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the first quarter ended March 31, 2022. "CollPlant continues to make important progress executing our internal pipeline and partnered programs, including our strategic agreement with AbbVie to co-develop dermal and soft fillers using our proprietary collagen technology.

CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results

REHOVOT, Israel , April 25, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that CEO Yehiel Tal will moderate the International Society for Biofabrication's (ISBF) virtual event on May 2 nd. Mr. Tal also serves as a board member of ISBF.

CollPlant CEO Yehiel Tal to Moderate ISBF's virtual event on Biofabrication of Microphysiological Systems for Drug Discovery and Screening

REHOVOT, Israel , April 13, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Dr. Jasmine Seror, CollPlant's Head of Aesthetic Medicine and Exploratory Products, will deliver a presentation at the Aesthetics Innovation Summit 2022, to be held in San Diego, California, on Wednesday, April 20, 2022.   The presentation, entitled "Novel photocurable rhCollagen implants for regenerative aesthetics applications," will be delivered virtually at the spotlight session on regenerative medicine & cell therapy at 11:20 AM EST.

CollPlant To Present at the Aesthetics Innovation Summit 2022

REHOVOT, Israel, March 24, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the fiscal year ended December 31, 2021. "2021 was a highly productive and transformative year for CollPlant's R&D and business development activities.

CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results

GOTHENBURG, Sweden and REHOVOT, Israel, Feb. 16, 2022 /PRNewswire/ -- Today, CELLINK, a BICO Group company (Nasdaq Stockholm: BICO) and a global leader in developing 3D bioprinting technologies which is expected to bridge the current gap and allow unlimited supply of life saving organs and CollPlant Biotechnologies (Nasdaq: CLGN) a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced they have signed a collaboration agreement. Under this collaboration, CELLINK's high-throughput, multi-material extrusion bioprinter will be explored for the development of large-scale production of CollPlant's 3D bioprinted regenerative breast implants, addressing a current market size of $2.8 billion, with 2.2 million procedures performed annually worldwide.

CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies

Preclinical modeling demonstrates potential for filler to enhance cell proliferation and new tissue regeneration for aesthetic medicine applications REHOVOT, Israel, Dec. 2, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the publication of an article in the Plastic and Reconstructive Surgery journal titled "The Potential Use of Novel Plant-Derived Recombinant Human Collagen in Aesthetic Medicine."  The article highlights favorable in-vitro and in-vivo results of CollPlant's photocurable dermal filler as well as other potential applications of this collagen technology in aesthetic medicine.

CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal

REHOVOT, Israel, Nov. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the third quarter ended September 30, 2021. "The recent commercial launch of Collink.3D represents an important inflection point for CollPlant in its efforts to become a market leader in the field of regenerative medicine.

CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results

REHOVOT, Israel, Nov. 15, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the launch of Collink.3D, a recombinant human collagen (rhCollagen)- based BioInk solution for use in 3D bioprinting. Collink.3D, CollPlant's first commercially available rhCollagen-based BioInk product is designed to allow the scalable and reproduceable biofabrication of scaffolds, tissues and organ transplants.

CollPlant Announces Commercial Launch of BioInk Platform with Collink.3D™ for Use in 3D Bioprinting of Human Tissues, Scaffolds and Organs

REHOVOT, Israel, Oct. 14, 2021 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the Company's Deputy CEO & Chief Financial Officer Eran Rotem, will present a company overview at the Dawson James 6th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida. Mr.

CollPlant to Present at Dawson James Small Cap Growth Conference on October 21st

REHOVOT, Israel, Oct. 11, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that its recombinant human collagen (rhCollagen)-based bioink was used successfully by researchers from Israel's Technion Institute of Technology to create a 3D bioprinted implantable tissue containing a network of blood vessels capable of supplying blood to the implanted tissue. "We are excited with the impressive and innovative work of our collaborators at the Technion," said Yehiel Tal, CollPlant's CEO.

CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs

REHOVOT, Israel, Sept. 30, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, has been invited to present at the Fall Harvest – Best Ideas from the Buy-Side conference, which is being held virtually on October 5th – 8th, 2021.

CollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021

REHOVOT, Israel, Sept. 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr.

CollPlant CEO Yehiel Tal to Discuss Emerging Uses of rhCollagen in Aesthetic and Regenerative Medicine at NANO.IL.2021 Conference

REHOVOT, Israel, Sept. 9, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr.

CollPlant CEO Yehiel Tal elected to the Board of Directors of the International Society for Biofabrication (ISBF)

REHOVOT, Israel, Sept. 7, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr.

CollPlant To Present at the H.C. Wainwright Annual Global Investment Conference in September

REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan.

CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors

Shares of CollPlant Biotechnologies (NASDAQ:CLGN) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 25.00% year over year to ($0.25), which missed the estimate of ($0.10).

Recap: CollPlant Biotechnologies Q2 Earnings

REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended June 30, 2021 and provided an update on the Company's business developments. "We are very excited with the momentum we are seeing in our efforts to leverage our plant-based human recombinant collagen platform and R&D capabilities to create products and collaborations that expand our addressable markets in medical aesthetics and 3D bioprinting," said Yehiel Tal, CollPlant's Chief Executive Officer.

CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results

REHOVOT, Israel, Aug. 16, 2021 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Dr. Nadav Orr, Vice President of R&D, will present on August 19, 2021, an overview on the use of collagen Bionks for 3D Bioprinting, during the Biomaterials For 3D Printing webinar by 3DHEALS LLC.  The presentation is titled "Collagen BioInk Platform for 3D Bioprinting of Tissues and Organs.

CollPlant Biotechnologies to Present on the Use of Collagen BioInk as a Platform for 3D Bioprinting of Tissues and Organs at the Biomaterials For 3D Printing Webinar

CLGN's platform-technology is underscored by its recent AbbVie partnership. Royalty model company that is debt-free, and well funded.

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

3D Systems

Stratasys

Five months ago, 3D Systems promised to expand into the "nascent industry" of printing entire human body parts. Today, it's doing just that.

Why 3D Systems, CollPlant BioTechnologies, and Stratasys Stocks Soared Today

REHOVOT, Israel, June 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced today the uplisting of its ordinary shares to the Nasdaq Global Select Market®  effective at the open of market today, Friday, June 4, 2021. CollPlant's ordinary shares now trade under the Company's current ticker symbol "CLGN" and the Company's American Depositary Shares (ADSs) have been mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio.

CollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs

REHOVOT, Israel, May 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on the Company's business developments. CollPlant reported revenues of $14.5 million for the first quarter of 2021, a 2,281% increase from the $609,000 recorded in the first quarter of 2020 resulting primarily from the $14 million upfront payment received from Allergan Aesthetics, an AbbVie company, in connection with the development agreement entered into in February 2021.

CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million

REHOVOT, Israel, May 25, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced that its ordinary shares have been approved for trading on the Nasdaq Global Market®  under the Company's current ticker symbol "CLGN" and will begin trading at the open of market on June 4, 2021. At such time, the Company's American Depositary Shares (ADSs) will be mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio.

CollPlant Announces Uplisting to the Nasdaq Global Market® and Transition to Trading of Ordinary Shares Instead of ADSs

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $14.68 in the latest trading session, marking a +1.91% move from the prior day.

News for CollPlant Biotechnologies Ltd - ADR Stock (CLGN)